EP1729800A4 - IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE - Google Patents

IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE

Info

Publication number
EP1729800A4
EP1729800A4 EP05724183A EP05724183A EP1729800A4 EP 1729800 A4 EP1729800 A4 EP 1729800A4 EP 05724183 A EP05724183 A EP 05724183A EP 05724183 A EP05724183 A EP 05724183A EP 1729800 A4 EP1729800 A4 EP 1729800A4
Authority
EP
European Patent Office
Prior art keywords
pneunomiae
chlamydia
immunogenic compositions
immunogenic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05724183A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1729800A2 (en
Inventor
Guido Grandi
Giulio Ratti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of EP1729800A2 publication Critical patent/EP1729800A2/en
Publication of EP1729800A4 publication Critical patent/EP1729800A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05724183A 2004-03-02 2005-03-02 IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE Withdrawn EP1729800A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54983204P 2004-03-02 2004-03-02
US64311005P 2005-01-12 2005-01-12
US64455205P 2005-01-19 2005-01-19
PCT/US2005/006588 WO2005084306A2 (en) 2004-03-02 2005-03-02 Immunogenic compositions for chlamydia pneunomiae

Publications (2)

Publication Number Publication Date
EP1729800A2 EP1729800A2 (en) 2006-12-13
EP1729800A4 true EP1729800A4 (en) 2008-06-11

Family

ID=34923269

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05724183A Withdrawn EP1729800A4 (en) 2004-03-02 2005-03-02 IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE

Country Status (6)

Country Link
EP (1) EP1729800A4 (ja)
JP (1) JP2007526318A (ja)
BR (1) BRPI0508365A (ja)
CA (1) CA2557353A1 (ja)
RU (1) RU2006134631A (ja)
WO (1) WO2005084306A2 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2351772B1 (en) 2005-02-18 2016-07-13 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
JP2011529171A (ja) * 2008-07-25 2011-12-01 セレスティス リミテッド 診断方法
WO2010032138A2 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
NZ598459A (en) 2009-08-27 2014-03-28 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
BR112013005134A2 (pt) 2010-09-01 2018-04-24 Novartis Ag adsorção de imunopotenciadores em sais metálicos insolúveis
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
JP6325986B2 (ja) 2012-03-07 2018-05-16 ノバルティス アーゲー 免疫学的に有用なアルギニン塩
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
JP6990522B2 (ja) 2017-04-11 2022-02-03 シスメックス株式会社 免疫細胞の免疫刺激応答性を測定する方法、免疫細胞における免疫シナプスの形成能を判定する方法及び細胞分析装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HENDERSON IAN R ET AL: "Polymorphic proteins of Chlamydia spp.-autotransporters beyond the Proteobacteria", TRENDS IN MICROBIOLOGY, vol. 9, no. 12, December 2001 (2001-12-01), pages 573 - 578, XP002477530, ISSN: 0966-842X *
VANDAHL BRIAN BERG ET AL: "The expression, processing and localization of polymorphic membrane proteins in Chlamydia pneumoniae strain CWL029.", BMC MICROBIOLOGY, vol. 2, no. 36 Cited January10, 2003, 26 November 2002 (2002-11-26), XP002477529, ISSN: 1471-2180 *

Also Published As

Publication number Publication date
CA2557353A1 (en) 2005-09-15
RU2006134631A (ru) 2008-04-10
JP2007526318A (ja) 2007-09-13
BRPI0508365A (pt) 2007-07-24
WO2005084306A2 (en) 2005-09-15
EP1729800A2 (en) 2006-12-13
WO2005084306A3 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
HUS2200002I1 (hu) Immunogén készítmény
EP1729800A4 (en) IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE
ZA200710384B (en) Immunogenic compositions for chlamydia trachomatis
IL181825A0 (en) Immunogenic composition
GB0406819D0 (en) Controlled release compositions
GB0526038D0 (en) Immunogenic composition
ZA200710853B (en) Immunogenic composition
GB0421079D0 (en) Immunogenic composition
ZA200710854B (en) Immunogenic composition
GB0402236D0 (en) Immunogenic compositions for chlamydia trachomatis
ZA200702752B (en) Immunogenic compositions
GB0315020D0 (en) Immunogenic compositions for chlamydia trachomatis
GB0421082D0 (en) Immunogenic composition
GB0421078D0 (en) Immunogenic composition
GB0421081D0 (en) Immunogenic composition
GB0526041D0 (en) Immunogenic composition
GB0526040D0 (en) Immunogenic composition
GB0524204D0 (en) Immunogenic composition
GB0515556D0 (en) Immunogenic composition
GB0503143D0 (en) Immunogenic composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061002

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RATTI, GIULIO

Inventor name: GRANDI, GUIDO

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RATTI, GIULIO

Inventor name: GRANDI, GUIDO

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080513

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081011